BFLY Stock Analysis: Butterfly Network | NYSE

Medical Devices | NYSE, USA | Market Cap: 2.153m USD | 12M Return: 326.7% | Charts, Fundamentals & Technical Analysis

Ultrasound Devices, Bladder Scanner, AI Platform, Veterinary
Total Rating 44
Safety 41
Buy Signal 0.77
Medical Devices
Industry Rotation: +0.0
Market Cap: 2.15B
Avg Turnover: 70.4M
Risk 3d forecast
Volatility101%
VaR 5th Pctl15.0%
VaR vs Median-10.3%
Reward TTM
Sharpe Ratio1.69
Rel. Str. IBD98.8
Rel. Str. Peer Group99.4
Character TTM
Beta1.196
Beta Downside0.617
Hurst Exponent0.428
Drawdowns 3y
Max DD73.20%
CAGR/Max DD0.70
CAGR/Mean DD1.24
EPS (Earnings per Share) EPS (Earnings per Share) of BFLY over the last years for every Quarter: "2021-06": -0.02, "2021-09": -0.23, "2021-12": -0.08, "2022-03": -0.22, "2022-06": -0.18, "2022-09": -0.26, "2022-12": -0.17, "2023-03": -0.16, "2023-06": -0.14, "2023-09": -0.12, "2023-12": -0.21, "2024-03": -0.1, "2024-06": -0.07, "2024-09": -0.05, "2024-12": -0.08, "2025-03": -0.04, "2025-06": -0.03, "2025-09": -0.04, "2025-12": -0.05, "2026-03": -0.03,
Last SUE: 1.53
Qual. Beats: 1
Revenue Revenue of BFLY over the last years for every Quarter: 2021-06: 16.513, 2021-09: 14.621, 2021-12: 18.987, 2022-03: 15.574, 2022-06: 19.215, 2022-09: 19.618, 2022-12: 18.983, 2023-03: 15.476, 2023-06: 18.487, 2023-09: 15.421, 2023-12: 16.516, 2024-03: 17.656, 2024-06: 21.487, 2024-09: 20.561, 2024-12: 22.351, 2025-03: 21.225, 2025-06: 23.383, 2025-09: 21.489, 2025-12: 31.514, 2026-03: 26.53,
Rev. CAGR: 16.63%
Rev. Trend: 93.8%
Last SUE: 0.33
Qual. Beats: 0

Warnings

Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone

Tailwinds

Rs Leader
Idiosyncratic Leader

Seasonality 5.9 years of data

Jan +1.6% 9
Feb -2.8% 10
Mar -11.6% 11
Apr +1.0% 9
May +1.6% 24
Jun -3.5% 10
Jul +12.7% 10
Aug +4.5% 10
Sep -12.4% 11
Oct +3.0% 10
Nov +16.9% 10
Dec +4.6% 10

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: BFLY Butterfly Network

Butterfly Network, Inc. (NYSE: BFLY) is a U.S.-based medical device company that designs, manufactures, and sells ultrasound imaging solutions for both human and veterinary use. Its core product line centers on handheld, single-probe ultrasound devices (Butterfly iQ+ and iQ3) that connect to smartphones, tablets, or hospital computer systems, along with complementary offerings such as the Butterfly Move cart-based system and the iQ+ Bladder specialty scanner. The company also generates revenue from software and services, including Compass AI (a workflow and device-management platform) and ScanLab (an AI-powered educational tool), reflecting a business model that combines hardware sales with recurring software and training revenue.

Butterfly sells through a direct sales force, third-party distributors, and e-commerce channels, and serves customers in the United States and internationally. Founded in 2011 and headquartered in Burlington, Massachusetts, Butterfly operates within the Health Care Equipment sub-industry of the broader medical devices sector, where point-of-care and portable ultrasound represent a growing segment relative to traditional cart-based systems used in hospitals and imaging centers.

Headlines to Watch Out For
  • iQ3 and Move adoption drives handheld ultrasound revenue growth
  • Compass AI and software subscriptions expand recurring high-margin revenue
  • International distribution expansion accelerates geographic revenue diversification
Piotroski VR-10 (Strict) 0.5
Net Income: -75.8m TTM > 0 and > 6% of Revenue
FCF/TA: -0.07 > 0.02 and ΔFCF/TA 4.28 > 1.0
NWC/Revenue: 175.1% < 20% (prev 251.0%; Δ -75.89% < -1%)
CFO/TA -0.05 > 3% & CFO -14.9m > Net Income -75.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.02 > 1.5 & < 3
Outstanding Shares: last quarter (256.5m) vs 12m ago 9.19% < -2%
Gross Margin: 49.21% > 18% (prev 60.65%; Δ -11.45% > 0.5%)
Asset Turnover: 34.06% > 50% (prev 26.89%; Δ 7.17% > 0%)
Interest Coverage Ratio: -52.22 > 6 (EBIT TTM -74.2m / Interest Expense TTM 1.42m)
Altman Z'' -5.57
A: 0.63 (Total Current Assets 239.8m - Total Current Liabilities 59.6m) / Total Assets 285.9m
B: -3.12 (Retained Earnings -891.9m / Total Assets 285.9m)
C: -0.25 (EBIT TTM -74.2m / Avg Total Assets 302.2m)
D: 2.02 (Book Value of Equity 191.2m / Total Liabilities 94.7m)
Altman-Z'' = -5.57 = D
Beneish M -2.84
DSRI: 1.05 (Receivables 25.2m/19.9m, Revenue 102.9m/85.6m)
GMI: 1.23 (GM 60.65% / 49.21%)
AQI: 0.68 (AQ_t 0.06 / AQ_t-1 0.09)
SGI: 1.20 (Revenue 102.9m / 85.6m)
TATA: -0.21 (NI -75.8m - CFO -14.9m) / TA 285.9m)
Beneish M = -2.84 (Cap -4..+1) = A
What is the price of BFLY shares?

As of July 11, 2026, the stock is trading at USD 7.98 with a total of 5,375,495 shares traded. Over the past week, the price has changed by +3.91%, over one month by +48.05%, over three months by +94.16% and over the past year by +326.74%.

Current recommended Stop Loss: 7.10 (which is 11% or 1.2 ATR below the current price).

Is BFLY a buy, sell or hold?

Butterfly Network has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy BFLY.

  • StrongBuy: 4
  • Buy: 0
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the BFLY price?
Analysts Target Price 7.1 -11.5%
Butterfly Network (BFLY) - Fundamental Data Overview as of 08 July 2026
Market Cap USD = 2.15b (2.15b USD * 1.0 USD.USD)
P/S = 20.9231
P/B = 10.5082
Revenue TTM = 102.9m USD
EBIT TTM = -74.2m USD
EBITDA TTM = -66.7m USD
Long Term Debt = 17.0m USD (estimated: total debt 19.8m - short term 2.74m)
Short Term Debt = 2.74m USD (from shortTermDebt, last quarter)
Debt = 19.8m USD (from shortLongTermDebtTotal, last quarter) (leases 19.8m already included)
Net Debt = -118.2m USD (calculated: Debt 19.8m - CCE 138.0m)
Enterprise Value = 2.04b USD (2.15b + Debt 19.8m - CCE 138.0m)
Interest Coverage Ratio = -52.22 (Ebit TTM -74.2m / Interest Expense TTM 1.42m)
EV/FCF = -107.9x (Enterprise Value 2.04b / FCF TTM -18.9m)
FCF Yield = -0.93% (FCF TTM -18.9m / Enterprise Value 2.04b)
FCF Margin = -18.33% (FCF TTM -18.9m / Revenue TTM 102.9m)
Net Margin = -73.63% (Net Income TTM -75.8m / Revenue TTM 102.9m)
Gross Margin = 49.21% ((Revenue TTM 102.9m - Cost of Revenue TTM 52.3m) / Revenue TTM)
Gross Margin QoQ = 68.92% (prev 67.34%)
Tobins Q-Ratio = 7.12 (Enterprise Value 2.04b / Total Assets 285.9m)
Interest Expense / Debt = 7.20% (Interest Expense 1.42m / Debt 19.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -58.7m (EBIT -74.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.02 (Total Current Assets 239.8m / Total Current Liabilities 59.6m)
Debt / Equity = 0.10 (Debt 19.8m / totalStockholderEquity, last quarter 191.2m)
 Debt / EBITDA = 1.77 (negative EBITDA) (Net Debt -118.2m / EBITDA -66.7m)
 Debt / FCF = 6.27 (negative FCF - burning cash) (Net Debt -118.2m / FCF TTM -18.9m)
 Total Stockholder Equity = 206.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -25.08% (Net Income -75.8m / Total Assets 285.9m)
RoE = -36.79% (Net Income TTM -75.8m / Total Stockholder Equity 206.0m)
RoCE = -33.30% (EBIT -74.2m / Capital Employed (Equity 206.0m + L.T.Debt 17.0m))
 RoIC = -26.19% (negative operating profit) (NOPAT -58.7m / Invested Capital 223.9m)
 WACC = 10.15% (E(2.15b)/V(2.17b) * Re(10.19%) + D(19.8m)/V(2.17b) * Rd(7.20%) * (1-Tc(0.21)))
Discount Rate = 10.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 9.94%
 [DCF] Fair Price = unknown (Cash Flow -18.9m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.53 | # QB: 1
Revenue Correlation: 93.77 | Revenue CAGR: 16.63% | SUE: 0.33 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.04 | Chg30d=N/A | Revisions=+25% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.04 | Chg30d=N/A | Revisions=+25% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.13 | Chg30d=+0.00% | Revisions=+40% | GrowthEPS=-6.2% | GrowthRev=+21.7%
EPS next Year (2027-12-31): EPS=-0.09 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+27.5% | GrowthRev=+19.7%
[Analyst] Revisions Ratio: +62% (up=5, down=0)